500 patients to help unlock secrets of rare histiocytosis disorders
NCT ID NCT07157683
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will collect blood, saliva, urine, and stool samples from 500 adults with systemic histiocytosis—a group of rare inflammatory disorders. Researchers aim to identify biomarkers that could improve diagnosis, predict disease progression, and enable less invasive monitoring. The study does not test any treatment but may guide future targeted therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better diagnostic tools and less invasive monitoring methods for systemic histiocytosis.
- What could go wrong
- This is an observational study that collects samples only—it does not test a treatment. The findings may not lead to immediate clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERDHEIM-CHESTER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Internal Medicine Department 2 at Pitié-Salpêtrière Hospital
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill tame a rare immune disease?
- Massive study tracks hidden toll of rare immune diseases
- Rare disease study probes hidden brain effects
- New hope for kids with rare cell disease: targeted pill tested
- New hope for kids with rare immune disorder: international trial tests drug cocktails
- Could existing cancer drugs tackle rare tumors? new trial aims to find out